跳转到主要内容


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
快速连接

白皮书

Semaglutide - Dr. Reddy’s Fully Synthetic Peptide API

Chemical Structure of Semaglutide

Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist, with 94% sequence homology to human GLP-1 indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.

In this whitepaper, we look at Dr. Reddy’s Semaglutide, a synthetic peptide identical to the innovator molecules. As the innovator molecule and unlike most generic versions in the market, it is neither a base addition salt (Sodium, Potassium, and the likes) nor an acid addition salt (Acetate, Trifluoroacetate, Hydrochloride, and the likes).

Dr. Reddy’s provides a unique end-to-end product offering where customers can choose from the following business models:

  • API purchase
  • API + device purchase
  • Combination of API and Salcaprozpate sodium (SNAC) for oral formulation
  • Finished formulations purchase

To know more about our API offerings, please read the White paper on Semaglutide by filling the contact from below.

Explore other Whitepapers:

Know More

Download Now

请填写下面的联系表以查看白皮书

给我们发电子邮件: api@drreddys.com | +91 40 49002222

免责声明

本目錄中的任何信息(包括對任何產品或服務的任何引用)均不構成銷售要約,或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是,只要存在此類監管豁免,就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估,並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途,但可用於第 107A 節。

X

Have you booked your
CPHI Japan meeting slot yet?

Join us at booth: 5N-12

17th-19th April 2024

East Halls 4, 5 & 6, Tokyo Big Sight, Tokyo, Japan

Schedule a meeting